GSK's medical director for oncology Dan Gregory says the reimbursement of ZEJULA (niraparib) marks a major milestone for the company and patients living with a form of cancer that is in desperate need of more innovative treatments. …
GSK's official return to oncology with listing of ovarian cancer therapy
September 1, 2022 Latest NewsBioPharmaBioPharmaDispatch ExecutiveNews of the Day
Latest Video
New Stories
-
OncoSil completes first production run at new Sydney manufacturing facility
December 17, 2025 - - Australian Biotech -
Island Pharmaceuticals secures key partnership with Texas Biomed
December 17, 2025 - - Australian Biotech -
Novartis names new Country President following leadership transition
December 16, 2025 - - Latest News -
Mayne Pharma opens expanded manufacturing facility after termination of takeover
December 16, 2025 - - Latest News -
Budget update includes impact of listings, but generally not much else
December 16, 2025 - - Latest News -
The UK reconfirms the direct impact of the transatlantic shift in medicine pricing
December 16, 2025 - - Latest News -
The industry is probably right to resist, it just needs to prepare for the response
December 16, 2025 - - Latest News